Open Accessibility Menu

Test to Treat Equity Program

You may be eligible for COVID-19 treatment:

  • You must start meds within 5 days of symptoms
  • Kaweah Health continues to maintain a supply of COVID-19 antiviral pills (Paxlovid) for treating eligible high risk patients 12 years of age and older

COVID-19 | Test to Treat Equity Program

In November of 2022, Kaweah Health was awarded the COVID-19 Test to Treat Equity Program Grant.

The COVID-19 Test to Treat Equity Program connects COVID-19 patients with therapeutic treatments to decrease related morbidity and mortality.

The California Department of Public Health (CDPH) has established the COVID-19 Therapeutics Equity Grant Program to expeditiously connect patients who test positive for COVID-19 with therapeutic treatment to decrease related morbidity and mortality.

CDPH supports Kaweah Health's access to clinically appropriate COVID-19 therapeutics in a timely manner with a focus on three key expedited elements of COVID-19 assessment and treatment (testing, prescribing and therapeutics).

Kaweah Health is a Test to Treat Equity Program Facility

  • FLYER - COVID-19 Treatments Questions & Answers - DOWNLOAD
    • COVID-19 treatments are safe, free, widely available, and highly effective at preventing COVID-19 illness from becoming serious. They can stop the virus from multiplying in your body, may help you test negative sooner, and may reduce the risk of developing long COVID symptoms.

  • FLYER - Who should take COVID-19 treatments? - DOWNLOAD

    • Everyone who has symptoms and tests positive for COVID-19 should seek evaluation for medications to treat COVID-19.

  • FLYER - COVID-19 Therapeutics Myths and Facts - DOWNLOAD

    • How to dispel misinformation about treatments

  • FLYER - COVID-19 Therapeutics Warmline California Department of Public Health - DOWNLOAD

    • 1-866-268-4322 (866-COVID-CA) Provider Warmline Support Now Available
      Beginning 1/9/2023, health care providers can call 1-866-268-4322 (COVID-CA) to receive free and confidential consultation on COVID-19 testing and treatment. The COVID-19 Therapeutics Warmline is a real-time resource available to all California health care providers and is managed by the University of California, San Francisco (UCSF) National Clinician Consultation Center.

  • FLYER - Notice of Patients’ Right to NOT be Charged for Paxlovid or Lagevrio (molnupiravir) - DOWNLOAD

    • Patients should never be charged for Paxlovid or Lagevrio (molnupiravir). All providers administering or supplying COVID-19 therapeutics distributed through the federal government signed an agreement to not charge patients for drug costs.

Web Links

California Department of Public Health -